Expression studies of the mutant LPL cDNA in COS-7 cells produced normal amounts of enzyme mass. However, the mutated LPL was not catalytically active, nor was it efficiently secreted from the cells. This established that the Gly --Glu substitution at amino acid 142 is sufficient to abolish enzymatic activity and to result in the chylomicronemia syndrome observed in these patients. (J. Clin.
Introduction
Familial chylomicronemia (type I hyperlipoproteinemia) is a rare disorder of lipid metabolism characterized by a massive increase in chylomicron levels in fasting plasma and a marked increase in plasma triglyceride levels (1) . This metabolic alteration is associated with a variety of clinical features, including recurrent abdominal pain, pancreatitis, hepatosplenomegaly, eruptive cutaneous xanthomas, and retinal lipemia (1) . Two variants, deficiencies of lipoprotein lipase (LPL)' (2) and of apolipoprotein C-Il (3), have been identified as causes of this disease. A rarer disorder, transmitted as an autosomal dominant trait, results from the presence ofa circulating inhibitor of LPL (4) . In addition, an autoimmune mechanism has been proposed in a recently reported case of chylomicronemia (5) .
LPL, the hydrolytic enzyme involved in a majority ofcases with familial chylomicronemia, plays a pivotal role in the metabolism of plasma lipoproteins (6, 7) . This enzyme is synthesized by the parenchymal cells of many tissues, most notably adipose tissue, heart and muscle, and is transported to the luminal surface ofvascular endothelial cells, where it presumably binds to heparan sulfate (8, 9) . At this site, LPL is rate-limiting for the hydrolysis and removal of triglycerides associated with chylomicrons and very low density lipoproteins (VLDL). Intravenous heparin releases LPL into the blood where its enzymatic activity (10, I 1) and its mass (12, 13) can be assayed. The absence or near absence of LPL activity in postheparin plasma establishes the diagnosis of LPL deficiency.
Functional LPL is a homodimeric glycoprotein with a subunit of 448 amino acids (14) . The LPL gene has been mapped to the short arm of human chromosome 8 (15) and recent genomic cloning has shown it to be composed of 10 exons spanning -30 kb (16, 17) . Genomic and cDNA sequence comparisons have localized a region on exons 4 and 5 demonstrating a remarkably high degree ofhomology to other lipases (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) and a significant homology to serine proteases (29) and Drosophila yolk proteins (30) . The availability ofthese human LPL clones and genomic sequence information has made possible two diagnostic approaches to assess directly the molecular basis of LPL deficiency. First, transmission of LPL mutations in families can be traced using restriction fragment length polymorphisms (RFLP). Recent studies utilizing this technique identified gross alterations in the LPL gene responsible for primary LPL deficiency in a significant number of type I hyperlipoproteinemias (31, 32) . An alternative and more sensitive approach, based on DNA sequence analysis, involves the direct identification of the deficiency-causing mutation in the LPL gene. Two recent studies have employed this technique to characterize the genetic defect of LPL-deficient individuals, both demonstrating a catalytically inactive enzyme and some impaired binding to heparin (33, 34) .
In this report, we searched for point mutations affecting the structural gene for LPL in two type I hyperlipoproteinemic siblings from a family ofNorthern European descent. The genomic sequence obtained revealed a single-base change in these individuals resulting in a substitution of glutamic acid for glycine at amino acid residue 142. This substitution occurs within a region ofthe LPL gene that is highly conserved among lipases from different species, suggesting that this region is essential for functional activity ofthese enzymes. Introduction ofthis mutation into the normal LPL cDNA and cellular expression stud-ies confirm that substitution of glutamic acid for glycine 142 is sufficient to virtually abolish enzymatic activity. Thus, this phenotype is consistent with the enzymatic deficiency in the type I hyperlipoproteinemic subjects described in this report.
Methods
Subjects. We studied five members of a family of northern European ancestry with LPL deficiency (Table I ). The proband, age 22, whose parents are first cousins and had received genetic counseling, was 3.5 kg at birth after a normal gestation period and was delivered at 42 wk. At age 27 d he had an episode of melena with normal upper GI series. The bleeding ceased after vitamin K treatment. Plasma triglyceride levels were 337 mmol/liter (30,000 mg/dl). The infant had lipemia retinalis and several eruptive xanthomas and no hepatosplenomegaly. On a fatfree formula, the serum triglycerides were 25.3 mmol/liter (2,250 mg/ dl) and 9.5 mmol/liter (844 mg/dl) by the 10th and 15th day, respectively. The proband has continued to eat a moderately low-fat diet and has maintained serum triglycerides below 11.2 mmol/liter (1,000 mg/ dl). Occasionally, xanthomas have recurred but he has had no abdominal pain or overt pancreatitis. His apolipoprotein E phenotype is E4/2 (35) . The appearance of his apolipoprotein C-II band is normal on isoelectric focusing (36) . A female sibling developed at 3 mo generalized eruptive xanthomas and had an episode of melena. Over the past 25 years she has had a history of recurrent abdominal discomfort, two episodes of acute pancreatitis, and recurrent eruptive xanthomas. She has frequently had triglyceride levels in the range of 22.5 mmol/liter (2,000 mg/dl); neither the liver nor the spleen have been enlarged. The second episode of pancreatitis occurred during the third month of her pregnancy. With a calorie-and fat-controlled diet, she had no further problems and delivered a normal infant. Her apolipoprotein C-II band appeared normal on isoelectric focusing; her apolipoprotein E phenotype is E2/2.
Preparation ofDNA and oligonucleotide primers. DNA was extracted either from peripheral-blood mononuclear cells or from Epstein-Barr-virus-transformed lymphoblastoid cell lines (37, 38) . Buffycoat leukocytes were isolated from blood collected into tubes containing EDTA (Vacutainer, Becton Dickinson, Rutherford, NJ). Chromosomal DNA was released by lysis of cells in 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.5 mM MgCl2, 0.5% Triton X-100, and 1% SDS containing 500 ug/ml of proteinase K (Merck, Darmstadt, FRG). The lysates were incubated for 16 h at 370C with gentle agitation. After extraction with phenol and chloroform, DNA was recovered by ethanol precipitation. DNA was dissolved at 37°C for 2 h before spectrophotometric quantitation. Oligonucleotide primers were synthesized on an model 38 1A synthesizer (Applied Biosystems, Inc., Foster City, CA) using the f-cyanoethyl phosphoraramidite method, and were purified by reverse-phase chromatography cartridges (OPC, Applied Biosystems, Inc.). The polymerase chain reaction (PCR) primers were constructed complementary to DNA sequences flanking exons 1-9 of the LPL gene (17) .
PCR amplification and direct sequence determination ofamplified DNA. Target sequences were amplified (39) in a 100-,ul reaction volume containing 0.5 Mg ofchromosomal DNA; 50 pmol ofeach oligonucleotide primer; 200 MM of each dATP, dCTP, dGTP, and dTTP; lx reaction buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.4, 3 mM MgCI2, 0.05% polysorbate (Tween) 20, 0.05% Triton X-100 (40), 200 Mg/ml of gelatin); and 2 U of Taq DNA polymerase (Stratagene, Inc., San Diego, CA). 30 cycles ofPCR amplification were performed on a thermocycler (Ericomp, San Diego, CA). Each cycle consisted of 1 min denaturation at 94°C, 1 min at 55°C to anneal the oligonucleotide primers to their target sequences, and 2 min at 72°C for chain elongation. Amplified DNA was desalted and excess oligonucleotide primers and deoxynucleotide triphosphates removed by spin-dialysis on a Centricon-30 microconcentrator (Amicon Corp., Danvers, MA) or by electroelution using 1% agarose gels. The PCR products were resolved by electrophoresis on 1.4% SeaKem agarose gels (FMC Corp., Marine Colloids Division, Rockland, IL) in Tris-borate buffer containing 0.5 Mg/ml of ethidium bromide (41) . Sequence analysis was performed with gel-purified PCR products using the dideoxy-chain termination method (42). 50% of the amplification product was denatured using 2N NaOH at room temperature for 10 min. The DNA was precipitated with ethanol and the resuspended product was annealed to 1 pmol of oligonucleotide primer for 20 min at 37°C. DNA was sequenced using [a35-S]dATP (600 Ci/mmol; Amersham Corp., Arlington Heights, IL) and T7 DNA polymerase (United States Biochemical Corp., Cleveland, OH). Sequencing reaction mixtures were subjected to electrophoresis on 6% acrylamide gels containing 8 M urea. Gels were exposed to Kodak XAR film for 48 h.
Site-directed mutagenesis and expression. The human cDNA clone for LPL was directionally transferred to the Sal I/Eco RI site of Phagescript (Stratagene, Inc.), an M-l 3-based bacteriophage. Oligonucleotide-directed mutagenesis was performed using materials and instructions from Amersham Corp. The mutant oligonucleotide consisted of 21 bases corresponding to codons 139-145 of normal human LPL except for the middle G residue in codon 142 which was changed to A, Lipoprotein lipase assays. LPL activity was assayed using synthetic triacylglycerol substrates (10, 43). 1 mU of enzyme activity represents the release of 1 nmol of free fatty acid per min. Enzyme mass was determined by a previously described enzyme-linked immunosorbent assay ( 1 2).
Results
To determine the molecular defect in familial chylomicronemia, we assessed the structure of the LPL gene in the two siblings with primary LPL deficiency ( Table I ). The enzyme deficiency was diagnosed by the greatly reduced postheparin plasma LPL activity. The structure of the complete LPL gene was investigated using Southern blot analysis with 32P-labeled LPL cDNA probes (LPL 35, 37, and 46; reference 14). No major alteration of the LPL gene was detected in the two LPLdeficient patients (data not shown). The LPL gene was then examined in detail, using the PCR technique (39) and doublestranded DNA sequence analysis (41) . To amplify LPL exons, we synthesized a pair of oligonucleotide primers specific for each exon. These primers were complementary to intron sequences flanking the individual exons, as illustrated for exon 4 in Fig. 1 . Additional primers were used to perform DNA sequence analysis. Using this approach, the nine coding exons of LPL were amplified and sequenced. When compared to a control subject and to the LPL cDNA sequence (14) , a single base change was observed in exon 4 in the two LPL-deficient subjects (Fig. 2) . The detected single base mutation, a G-to-A transition at nucleotide position 680, results in replacement of a glycine (GGA) by a glutamic acid (GAA) at amino acid position 142. This finding was verified by determining the gene sequence for the complementary strands. To trace the inheritance of the observed mutation, three key members of the affected family, the father, the mother, and the paternal grandfather were analyzed. DNA sequence determination for these three family members demonstrated heterozygosity for the observed mutation (Fig. 2) .
To assess whether the observed amino acid substitution could be responsible for the decrease in enzymatic activity, we compared the primary structure from four mammalian species (human, cow, mouse, guinea pig) and one avian species (chicken) in the region surrounding the mutation (Fig. 3) . Within the highly conserved domain between glycine-130 and threonine-145, only two interspecies polymorphisms exist; isoleucine-140 in the human LPL is replaced with valine in the murine and cavian enzymes. In addition, leucine-144 in the human LPL is replaced with arginine in the cavian enzyme. Strikingly, glycine-142, the site ofthe observed mutation in the human LPL-deficient patients, is conserved in all five species of LPL (Fig. 3) , as well as in other lipase family members (not shown). These data suggest that this conserved amino acid is required for normal lipolytic function.
To determine whether the substitution ofglutamic acid for glycine observed in the LPL-deficient kindred could be responsible for the absence of enzymatic activity, we used sitedirected mutagenesis to introduce that mutation into normal LPL cDNA. Expression studies in COS-7 cells produced a mutated lipase that had little detectable hydrolytic activity when compared with the expression of native LPL (Fig. 4 A) . However, LPL mass determinations indicate that the mutant lipase is present intracellularly to at least the same levels as the controls (Fig. 4 B) . Further, the mutant lipase mass was drastically reduced in the media of these cells, suggesting decreased secretion of the mutant protein (Fig. 4 B) . Interestingly, LPL mass determination in the LPL-deficient proband demonstrated a low but measurable enzyme mass of 40 ng/ml of post-heparin plasma (Table I) cient phenotype we have shown by in vitro expression studies that substitution of glutamic acid for glycine at amino acid residue 142 of human LPL produces an aberrant lipase which is catalytically inactive and is not efficiently secreted.
Discussion
We have analyzed nine exons comprising the complete coding region of the LPL gene in two subjects from a kindred with familial LPL deficiency. A single missense mutation was iden- Gly -Ser -Gly Figure 3 . Region surrounding the nonconservative amino acid substitution (glycine-142 to glutamic acid) in four mammalian and one avian species. The normal human amino acid sequence for LPL (14) and the mutant with the substitution of glutamic acid for glycine (shown in box) are compared to the analogous sequences of bovine (21), murine (22) , cavian (23) , and avian (24) enzymes. The consensus sequence, glycine-x-serine-x-glycine, is encountered in all known lipases, some esterases, and a wide variety of serine proteases (29) . Dashes indicate amino acid identity with the normal human sequence.
tified in exon 4 ofthese two LPL-deficient patients. This mutation, a G-to-A transition at nucleotide 680, results in the substitution ofglutamic acid for glycine at position 142 (Fig. 2 ). Both (Fig. 2) .
Analysis of evolutionary relationships among different lipase genes shows that LPL is a highly conserved protein (26) . In particular, the amino acid sequence surrounding glycine-142 is highly homologous in the several mammals whose LPL sequences are known (Fig. 3) ; glycine is the only residue utilized at the analogous position in these species. The reason for this high local sequence conservation perhaps derives from its proximity to the catalytic center ofthe enzyme. LPL serine-132 has been proposed as the catalytic serine on the basis of sequence homologies with a variety of serine esterases (44) . This is supported by two recent experiments. First, human pancreatic lipase was recently crystallized and the three-dimensional structure shows serine-152 (analogous to human LPL serine-132) to be part of an aspartate/histidine/serine triad proposed to be essential for catalysis (45) . Second, conservative amino acid substitution at the analogous residue in rat hepatic lipase (serine-147) dramatically reduces catalytic activity (44) . Thus, the mutation identified in this kindred which substitutes a large, negatively charged glutamic acid in place of a small, neutral glycine residue within 10 amino acids of the proposed active site may be expected to disrupt enzymatic function.
The functional consequences ofthe detected mutation were confirmed utilizing site-directed mutagenesis to introduce the codon-142 mutation in the normal LPL cDNA. Expression studies indicated that mammalian cells transfected with the LPL mutant produced normal amounts of enzyme mass. The mutated LPL was not catalytically competent, nor was it efficiently released into the culture media. These results strongly suggest that the glutamic acid for glycine substitution at position 142 has a major adverse effect on the tertiary structure of the LPL molecule leading to a functionally deficient protein. Thus, the properties of the expressed mutant LPL were found to be consistent with the LPL-deficient phenotype observed in the proband.
LPL gene aberrations may be due to gross alterations or to specific point mutations. Recently, DNA analyses employing Southern hybridization indicated that gross alterations in the LPL gene in the form of insertion/deletion-type changes and duplication events were responsible for primary LPL deficiency in a significant number of type I hyperlipoproteinemic subjects (31, 32) . LPL deficiency may also arise from mutations resulting in minor changes in enzyme structure that affect various properties, such as enzymatic half-life, substrate affinity, interaction with heparan sulphate or with the cofactor apolipoprotein C-II. The mutation described in this report points to a single base change at amino acid 142, in very close proximity to the putative catalytically active site serine 132. The recent mutational analysis of two additional pedigrees has shown effects of point mutations in other regions of the LPL molecule (33, 34) . Sequence analysis of a kindred from Bethesda has revealed a single amino acid substitution of Ala for Thr at position 176, leading to an inactive enzyme with reduced binding to heparin (33) . A large family of Northern European ancestry was found to be LPL-deficient due to an amino acid substitution of Gly-188 to Glu, likewise resulting in a catalytically inactive protein with a lower affinity for heparin (34 In addition to homozygous LPL-deficient subjects, the much larger population of heterozygotes carrying various LPL mutations may also be clinically affected. Although not evident in this kindred, some heterozygous LPL-deficient subjects have recently been shown to have familial combined hyperlipidemia (13, 46) which manifests itself as hypertriglyceridemia, hypercholesterolemia, or a combination of both. This condition is associated with premature atherosclerosis (47) (48) (49) . Thus, heterozygous LPL-deficient patients in which mutations in the LPL gene may affect normal enzymatic function appear to form a subset of familial combined hyperlipidemia. The PCR technique in conjunction with direct DNA sequence analysis utilized in this study will undoubtedly facilitate the characterization of the structural variants of LPL. These variants will further aid in characterizing the possible role of LPL mutations in type I hyperlipoproteinemia, familial combined hyperlipidemia, and related disorders of lipid metabolism.
